Literature DB >> 10897110

Urokinase receptor up-regulation in head and neck squamous cell carcinoma.

M Schmidt1, G Schler, P Gruensfelder, J Müller, F Hoppe.   

Abstract

BACKGROUND: Urokinase-type plasminogen activator is important for matrix degradation and motility of cancer cells. For effective invasion, urokinase has to be associated with its cell surface receptor.(1)
METHODS: We analyzed 33 head and neck squamous cell carcinomas (hnSCC) and 14 mucosal tissue samples for the expression of urokinase receptor using Northern hybridization and correlated expression levels to clinical and histopathologic data. Urokinase expression was determined by fibrin zymography.
RESULTS: The expression of urokinase receptor is significantly increased in hnSCC compared with adjacent mucosa. Expression levels in primary tumors show no statistically significant correlations to T staging, metastasis, recurrence, or differentiation stage of the resected tumors. Furthermore, there was no correlation between urokinase and urokinase receptor expression levels in SCC samples.
CONCLUSIONS: Urokinase receptor expression is increased in hnSCC, but it is not useful as a prognostic marker for the metastatic behavior of primary tumors. Comparison of our data with previously published reports is discussed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10897110     DOI: 10.1002/1097-0347(200008)22:5<498::aid-hed9>3.0.co;2-w

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  5 in total

1.  The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Authors:  Jens E Meyer; Carsten Brocks; Hendrik Graefe; Carola Mala; Natalie Thäns; Markus Bürgle; Annette Rempel; Nicole Rotter; Barbara Wollenberg; Stephan Lang
Journal:  Breast Care (Basel)       Date:  2008-10-16       Impact factor: 2.860

Review 2.  Matrix metalloproteases in head and neck cancer.

Authors:  Eben L Rosenthal; Lynn M Matrisian
Journal:  Head Neck       Date:  2006-07       Impact factor: 3.147

3.  Efficient targeting of head and neck squamous cell carcinoma by systemic administration of a dual uPA and MMP-activated engineered anthrax toxin.

Authors:  Jeffrey M Schafer; Diane E Peters; Thomas Morley; Shihui Liu; Alfredo A Molinolo; Stephen H Leppla; Thomas H Bugge
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

4.  Prognostic value analysis of urokinase-type plasminogen activator receptor in oral squamous cell carcinoma: an immunohistochemical study.

Authors:  Roberta Bacchiocchi; Corrado Rubini; Elisa Pierpaoli; Giulia Borghetti; Pasquale Procacci; Pier Francesco Nocini; Andrea Santarelli; Romina Rocchetti; Domenico Ciavarella; Lorenzo Lo Muzio; Francesca Fazioli
Journal:  BMC Cancer       Date:  2008-08-01       Impact factor: 4.430

Review 5.  uPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.

Authors:  Miguel Angel Pavón; Irene Arroyo-Solera; Maria Virtudes Céspedes; Isolda Casanova; Xavier León; Ramón Mangues
Journal:  Oncotarget       Date:  2016-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.